Vancouver, BC – In a landmark achievement that heralds a new era for personalized pediatric cancer treatment, a pioneering pan-Canadian research team has unveiled a novel strategy to rapidly identify and test tailored therapies for young patients facing aggressive, treatment-resistant cancers. The innovative approach, detailed today in the prestigious journal EMBO Molecular Medicine, combines the groundbreaking technique of growing patient tumours in chicken eggs – creating "living avatars" – with advanced protein analysis, known as proteomics, to pinpoint and validate effective drug candidates in a matter of weeks.
Led by researchers from the University of British Columbia (UBC) and BC Children’s Hospital Research Institute (BCCHR), this collaborative effort marks the first time in Canada that these two sophisticated methodologies have been successfully integrated to inform real-time clinical decisions for a young cancer patient. The team’s success in identifying a new treatment for a child whose rare cancer had defied conventional therapies underscores the critical value of proteomics as a vital complement to the established practice of genomics in the urgent landscape of cancer care.
This monumental work is a testament to the power of national collaboration, fostered under the umbrella of PROFYLE (PRecision Oncology For Young peopLE), a flagship initiative of ACCESS (Advancing Childhood Cancer Experience, Science and Survivorship). This extensive Canadian pediatric cancer network unites over 30 research and funding organizations and more than 100 investigators from coast to coast, all dedicated to improving outcomes for children and young adults battling cancer. The study illuminates a promising pathway forward, offering renewed hope for families grappling with the devastating realities of hard-to-treat pediatric malignancies.
The Unyielding Battle Against Pediatric Cancer
Childhood cancer remains a formidable challenge, distinct in many ways from adult cancers. While overall survival rates have significantly improved over decades, a substantial proportion of young patients continue to face aggressive forms of the disease that are resistant to conventional chemotherapy and radiation. For these children, treatment options quickly dwindle, and the window for intervention is often narrow. Rare pediatric cancers, in particular, present unique diagnostic and therapeutic dilemmas due often to their uncommon molecular profiles and the scarcity of established treatment protocols. The standard approach often involves a trial-and-error method, which consumes precious time and can expose young bodies to harsh, ineffective drugs, compounding their suffering and diminishing their chances of recovery.
The limitations of traditional treatment paradigms, coupled with the unique biological complexities of pediatric tumours, underscore the urgent need for more precise, rapid, and personalized therapeutic strategies. This is where the integration of advanced molecular profiling and functional testing becomes not just beneficial, but critical for those children for whom standard care has failed. The ability to quickly pivot and identify new vulnerabilities in a tumour, and then test potential drugs against it, represents a paradigm shift in how these desperate cases can be managed.
A Patient’s Desperate Plea and a Scientific Pivot
The genesis of this groundbreaking study lies in the harrowing journey of an unnamed young patient, diagnosed with a rare pediatric cancer that proved stubbornly resistant to standard treatments. This child’s case epitomized the dire challenges faced by clinicians when conventional pathways are exhausted. Following the failure of initial chemotherapy, the medical team turned to genomic sequencing, the study of the tumour’s genetic makeup, hoping to uncover actionable mutations that could guide targeted therapy. Genomics has revolutionized oncology, providing a blueprint of a tumour’s genetic abnormalities. However, in this specific and increasingly common scenario, genomic testing failed to yield clear drug candidates. The tumour had not only resisted standard chemotherapy but also developed resistance to a drug initially selected based on its genetic profile, leaving the patient and their family with dwindling options.
This critical juncture prompted the research team, co-led by Dr. Georgina Barnabas, a postdoctoral researcher in Dr. Philipp Lange’s lab, and Tariq Bhat, a PhD student in Dr. James Lim’s lab, to explore an alternative, complementary avenue: proteomics. While genes (DNA) carry the instructions, proteins are the actual functional workhorses of every cell, executing cellular processes and mediating drug responses. Most drugs exert their effects by interacting with and modifying the activity of proteins. The researchers hypothesized that by analyzing the tumour’s proteome – its complete set of proteins – they might uncover "hidden weaknesses" or metabolic dependencies that genetic analysis alone could not reveal.
"With genomics alone, we couldn’t find a clear treatment option," articulated Dr. Lange, a senior investigator with the Michael Cuccione Childhood Cancer Research Program at BCCHR, alongside Dr. Lim and clinician Dr. Rebecca Deyell. "But by looking at the tumour’s proteins, we found a critical metabolic weakness that we could target with an already approved drug." This shift in focus proved pivotal. The proteomic analysis uncovered a crucial metabolic vulnerability: the tumour’s heavy reliance on an enzyme called SHMT2 (serine hydroxymethyltransferase 2). This enzyme plays a vital role in cellular metabolism, particularly in the pathways that produce building blocks essential for rapid cell division – a hallmark of cancer.
Proteomics: Unveiling the Tumour’s Achilles’ Heel
The distinction between genomics and proteomics, though often intertwined, is fundamental to understanding this breakthrough. Genomics provides a static snapshot of the genetic instructions within a cell, revealing potential mutations that might drive cancer growth. However, a gene mutation doesn’t always translate into an active, targetable protein. Proteins, on the other hand, are the dynamic machinery of the cell, constantly being made, modified, and degraded. They are the direct mediators of cell function and, crucially, the direct targets of the vast majority of therapeutic drugs.
When genomic testing failed to identify an effective pathway, the team pivoted to proteomics. This sophisticated technique involves extracting all proteins from a tumour sample and then using mass spectrometry and other analytical tools to identify, quantify, and characterize them. By meticulously mapping the tumour’s protein landscape, the researchers could discern which proteins were overactive, underactive, or abnormally modified – essentially, creating a functional blueprint of the cancer cell’s actual state and activity.
In the case of the young patient, this deep dive into the proteome revealed the tumour’s unexpected dependence on SHMT2. This enzyme is critical for the one-carbon metabolism pathway, which is essential for nucleotide synthesis (DNA and RNA building blocks) and amino acid metabolism, both of which are highly active in rapidly proliferating cancer cells. By inhibiting SHMT2, the team reasoned they could effectively "starve" the tumour by cutting off its access to a key energy and growth source. The next challenge was finding a drug that could specifically target SHMT2. Remarkably, their research led them to sertraline, a common antidepressant already approved for human use, which had been previously identified to inhibit SHMT2 activity. The repurposing of an existing drug offered a significant advantage, bypassing lengthy and costly development and approval processes, thereby accelerating the timeline for potential patient benefit.
The Avian Avatar: Accelerating Personalized Medicine
Identifying a potential drug target and a corresponding therapeutic agent is only half the battle. The critical next step is to determine if that drug will actually work against that specific patient’s tumour. Traditional methods for testing drug efficacy, such as culturing tumour cells in petri dishes or implanting them into mice, can be time-consuming, expensive, and may not accurately reflect the complex microenvironment of a human tumour. This is where the ingenious "chicken egg avatar" model proved invaluable.
The team employed a method that involves taking a small piece of the patient’s tumour tissue and carefully implanting it onto the chorioallantoic membrane (CAM) of a developing chicken embryo. The CAM is a highly vascularized extraembryonic membrane that provides an ideal, nutrient-rich environment for the human tumour to grow. Within a matter of weeks, the implanted tumour piece establishes itself, growing into a "living avatar" that closely mimics the original patient’s tumour, retaining its histological features, genetic profile, and, crucially, its drug response characteristics.
This innovative avatar system, part of the BRAvE initiative (Better Responses through Avatars and Evidence) at BCCHR which actively bridges clinical needs with research capabilities, offers several critical advantages. Firstly, it drastically speeds up the drug testing process. While traditional animal models can take months to yield results, the chicken egg model can provide personalized drug responses in as little as two to three weeks. This rapid turnaround is paramount when dealing with aggressive, fast-growing cancers in children where time is of the essence. Secondly, it provides a functional platform to directly test the efficacy of identified drugs on a living, complex tumour system, rather than relying solely on genomic predictions or in vitro models that may not fully capture the tumour’s biological intricacies.
"This technique speeds up the process of evaluating a treatment option in a way that simply wouldn’t be possible with traditional methods," explained Dr. Lim. "We could quickly confirm whether the drug we identified through proteomics could actually work for the patient’s tumour." By testing sertraline on the patient’s tumour avatar grown in the chicken egg, the researchers were able to confirm its inhibitory effect on the tumour’s growth, providing crucial evidence to support its use in the patient.
A Unified Front: The Power of Pan-Canadian Collaboration
This scientific triumph is not merely the result of individual brilliance but a testament to the unparalleled strength of collaborative research. The project was deeply embedded within PROFYLE (PRecision Oncology For Young peopLE), a visionary initiative designed to bring precision medicine to children and young adults with hard-to-treat cancers across Canada. PROFYLE, a key program of ACCESS (Advancing Childhood Cancer Experience, Science and Survivorship), is a sprawling network that mobilizes over 30 research and funding organizations and more than 100 investigators from various disciplines and institutions nationwide.
The PROFYLE framework enabled the seamless integration of diverse expertise – from pediatric oncologists and surgeons to molecular biologists, proteomic specialists, and bioinformaticians. It facilitated the sharing of rare patient samples, cutting-edge technologies, and specialized knowledge across institutional boundaries, transforming what might have been isolated efforts into a unified, impactful force. This collaborative ecosystem is vital for pediatric oncology, where patient numbers for specific rare cancers are small, making it challenging for any single centre to accumulate enough data or expertise.
The patient’s case, along with the scientific findings, was presented to a panel of experts established by PROFYLE. This multidisciplinary board, comprising leading pediatric oncologists, pathologists, and researchers from across the country, rigorously reviewed the data, discussed the implications, and ultimately endorsed sertraline as the most promising treatment option for the patient at that critical juncture. This peer review and consensus-building mechanism inherent to PROFYLE ensures that the personalized recommendations are robust, evidence-based, and benefit from the collective wisdom of Canada’s top minds in pediatric cancer.
Clinical Application and Initial Outcomes
Based on the compelling evidence from the proteomic analysis and the functional validation in the chicken egg avatar model, and with the endorsement of the PROFYLE expert panel, sertraline was administered to the young patient. The results, while not a complete cure, were nonetheless profoundly encouraging. Following the initiation of sertraline treatment, the patient’s tumour growth significantly slowed, providing much-needed respite and demonstrating the clinical utility of this novel approach. This outcome, though requiring additional treatments, underscored the potential for these personalized strategies to extend lives and improve the quality of life for children with limited options.
The ability to deliver a personalized treatment recommendation fast enough to actually impact a patient’s care trajectory is a critical metric for success in precision oncology. This study clearly demonstrated that the combined proteomics and avatar model could meet this demanding timeline, moving from discovery to clinical recommendation in a matter of weeks – a speed unprecedented in many traditional research pipelines.
Expert Perspectives and the Road Ahead
The success of this study has elicited a strong sense of optimism within the scientific and medical communities. Dr. Rebecca Deyell, a senior clinician involved in the Michael Cuccione Childhood Cancer Research Program, emphasized the profound clinical implications: "For patients whose cancers have exhausted standard options, every additional treatment avenue is a lifeline. This approach offers a systematic, data-driven way to find those lifelines faster."
Dr. Lange echoed this sentiment, highlighting the broader vision: "While there is more work to be done, this study shows that our approach can deliver personalized treatment recommendations fast enough to actually help patients with rare and difficult-to-treat cancers. We now hope to expand this method to other children to identify effective treatments faster across the country." The aspiration is to integrate this dual strategy of proteomics and avatar testing into the standard diagnostic and treatment workflow for pediatric oncology, particularly for relapsed or refractory cases.
The journey ahead involves further refinement and expansion of these techniques. Researchers will continue to explore other metabolic vulnerabilities and drug repurposing opportunities identified through proteomics. The chicken egg avatar model itself will be subject to ongoing validation and optimization to ensure its reliability and reproducibility across various tumour types. Furthermore, the ethical considerations and logistical challenges of implementing such advanced technologies on a larger scale across diverse healthcare settings will need to be carefully addressed. Funding for continued research and infrastructure development will be paramount to translate these promising early results into widespread clinical benefit.
Towards a New Era of Precision Pediatric Oncology
The Canadian team’s breakthrough represents a significant leap forward in the quest for precision medicine in pediatric oncology. By combining the deep molecular insights of proteomics with the rapid functional validation offered by living tumour avatars, they have forged a powerful new tool capable of navigating the complexities of resistant childhood cancers. This approach offers a beacon of hope for young patients and their families, providing a systematic way to uncover hidden therapeutic opportunities when all other avenues have been exhausted.
The success of this pan-Canadian collaboration also serves as a powerful testament to the impact of coordinated national research efforts. By pooling resources, expertise, and patient data, networks like PROFYLE and ACCESS are accelerating the pace of discovery and ensuring that groundbreaking innovations reach the children who need them most, regardless of their geographical location. As this method is expanded and refined, it holds the potential to transform the landscape of pediatric cancer treatment, ushering in an era where personalized, rapid, and effective therapies become the standard of care for every young patient battling this relentless disease. The fight against childhood cancer is far from over, but with innovations like these, the future looks brighter for countless children and their families across Canada and beyond.
About the Author
